News Alkermes closing in on Biogen with MS rival ALKS 8700 may have fewer side effects than Tecfidera.
News Apitope to develop MS drug, Merck KGaA tie-up ends Anglo-Belgian biotech will continue clinical development.
News Biogen takes on Tecfidera adherence issues Company hopes to coach patients with stomach side-effects.
News Novartis drug effective in advanced MS Siponimod slowed disability progression in secondary progressive multiple sclerosis
News Scangos to leave Biogen at a crossroads Company has grown, but direction towards next stage is unclear
News Sanofi's Dupixent scores double COPD win in US, China Originally anticipated in June, the FDA action stands to make Sanofi and Regeneron's biologic blockbuster even bigger.
Sales & Marketing Sponsored Shifting the paradigm in pharma marketing with content trans... Content transformation is changing pharmaceutical marketing. Join us to learn new strategies and approaches for this new world of patient centricity.